MAPK1 and neoplasm: More detailed quantitative studies on the inhibition of AKT and ERK phosphorylation and the effects on the expression of other predictive biomarkers on tumor cells, such as PD-L1, DNA mismatch repair (MMR) system, in correlation with the treatment schedules, time, and dose administration of the azasteroid alkylators in vivo, are currently under investigation.